News Corporation filed a Form 8-K on August 27, 2026, reporting that it provided daily stock repurchase transaction disclosures to the Australian Securities Exchange on August 26, 2026, as required under ASX rules.
KKR & Co. Inc. filed an 8-K on August 26, 2026, disclosing that it entered into a Stipulation and Order with the Antitrust Division of the Department of Justice to resolve a civil antitrust complaint related to premerger notification requirements under the Hart-Scott-Rodino Act …
Burlington Stores, Inc. filed a current report on August 27, 2026, announcing the availability of its operating results for the second fiscal quarter ended August 1, 2026, via an attached press release.
Dine Brands Global, Inc. filed a Form 8-K on August 27, 2026, disclosing that board member Howard M. Berk notified the company of his retirement from the Board of Directors, effective September 3, 2026.
Velocity Financial, Inc. filed an 8-K on August 27, 2026, disclosing that its wholly-owned subsidiary, Velocity Commercial Capital, LLC, entered into an Equity Purchase Agreement on August 26, 2026, to acquire equity interests in entities to be formed through a statutory division of Toorak …
Nabors Industries Ltd. filed a Form 8-K with the SEC on August 27, 2026, disclosing the August 26, 2026 closing of a Series B Preferred Stock purchase agreement with Quaise Energy, Inc., in which Nabors issued 391,944 common shares as consideration for a stake …
Karman Holdings Inc. filed a Form 8-K with the SEC on August 27, 2026, disclosing the appointment of Chris Boynton as Executive Vice President and Chief Financial Officer, effective September 14, 2026, and the planned departure of current CFO Mike Willis.
Graham Corporation filed a Form 8-K on August 27, 2026, disclosing the results of its Annual Meeting of Stockholders held on August 25, 2026, covering director elections, an advisory compensation vote, and auditor ratification.
The Scotts Miracle-Gro Company filed a Form 8-K on August 27, 2026, disclosing that it entered into a Third Amendment to its Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A. on August 24, 2026, extending the facility's Purchase Termination Date by one year.
MBX Biosciences, Inc. filed a current report on August 27, 2026 disclosing that the first patient had been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism.